BofA reiterates Cencora stock rating on retina business expansion By Investing.com

Cencora agreed to acquire EyeSouth Partners' retina business for $1.1 billion, which would expand its physician count from ~300 to >700 and lift retina market share to roughly 3%+. The company reaffirmed fiscal 2026 guidance and does not expect the deal to close in FY26; Cencora has a $63.6B market cap, a P/E of 39.6 and 7.5% LTM revenue growth. BofA maintained a Neutral rating with a $380 target while Evercore ISI and Leerink retained Outperform ratings with $420 and $447 targets, respectively. CFO James Cleary, CFO for >7 years, will retire but remain an advisor through year-end as a successor is sought.

Analysis

The transaction is best viewed as a platform-building bolt-on rather than a transformational purchase — it materially increases Cencora’s foothold in a niche clinical vertical and changes negotiating dynamics with suppliers and payors. By aggregating clinicians under a single specialty services umbrella, Cencora can compress unit costs for specialty injectables, steer purchasing volume toward its distribution channels, and accelerate biosimilar take‑rate vs a fragmented supply base. Expect the biggest margin impact to come from procurement leverage and higher clinic throughput rather than immediate revenue multiple expansion.

Execution risk is the dominant near-term variable: successful integration requires harmonizing physician compensation, payor contracts, and site-of-service coding across disparate practices — a 6–18 month operational window where patient volumes and billing cadence can wobble. Market expectations already embed growth, so any slip in cadence or slower biosimilar adoption will be punished more severely; conversely, faster-than-expected conversion to proprietary specialty services could produce asymmetric upside. Monitor reimbursement edits and headcount metrics at the practice level as leading indicators of integration health.

Management transition and capital allocation posture create a bifurcated path for returns. If leadership maintains disciplined M&A pricing and prioritizes margin capture over aggressive roll‑outs, the move compounds long-term optionality for further consolidation in ophthalmology. But distracted stewardship or an acceleration of aggressive, high-premium add-ons would widen downside volatility and compress multiple re-rating potential over the next 12–24 months.

Key Decisions for Investors

• Buy COR long-dated call spread (12–18 month LEAPs): long near‑ATM call, short a 25–30% OTM call to finance cost. Size 2–4% of portfolio; target 40–60% upside if platform synergies realize; cut to 50% exposure on a 15–20% realized integration miss.
• Equity entry on weakness: accumulate COR on a 10–15% intra‑quarter pullback with a 12‑month horizon, hedge with 3–6 month covered calls to monetize premium and protect downside; stop-loss 20% to limit execution risk.
• Long EVR (Evercore) 6–12 month exposure to capture incremental M&A advisory flows in healthcare: small size (1–2% NAV), target 20–30% upside if sector deal volume stays elevated; tighten on any signs of gross deal count decline.
• Event pair (risk‑reduce): long COR / short a regional ophthalmology consolidator of your choice to isolate payoff from integration and centralized distribution gains. Make pair size neutral and monitor physician retention metrics; unwind if physician attrition exceeds high single digits within three quarters.